目的 探讨血液病患者血清α-L-岩藻糖苷酶检测的临床意义.方法 54例血液病患者治疗前及治疗好转后分别检测α-L-岩藻糖苷酶；同时选取40名健康对照者,分析不同血液病患者间、血液病患者治疗前及治疗好转后α-L-岩藻糖苷酶的变化情况.结果 血液病患者的α-L-岩藻糖苷酶明显高于健康对照组(P＜0.05)；治疗前骨髓增生异常综合征组的α-L-岩藻糖苷酶水平低于其他血液病组(P＜0.05)；治疗前急性淋巴细胞白血病组的α-L-岩藻糖苷酶水平高于慢性粒细胞白血病组(P＜0.05)；其余血液病患者治疗组间的d-L-岩藻糖苷酶水平无统计学差异(P＞0.05)；治疗后各血液病患者组间的α-L-岩藻糖苷酶水平无显著性差异(P＞0.05)；血液病患者治疗好转后,各血液病组的α-L-岩藻糖苷酶水平较治疗前明显降低(P＜0.05).结论 α-L-岩藻糖苷酶可作为判断血液病患者治疗效果的参考指标.%Objective To discuss the clinical significance of detection of a - L - fucosidase in patients with hematopathy. Methods Detection of a - L - fucosidase was made among 54 patients with hematopathy before and after the treatment. At the same time, 40 healthy people were selected as the control group. The changes of a - L - fucosidase level were analyzed among all subjects with different blood diseases before and after the treatment. Results The a - L - fucosidase level in patients with hematopathy were significantly higher than that in the control group (P <0. 05) ; this parameter in patients with bone marrow hyperplasia syndrome were significantly lower than that in ones with other blood diseases before the treatment (P <0. 05) ; it in patients with acute lymphoblastic leukemia were significantly higher than that in ones with chronic myelocytic leukemia before the treatment (P<0.05). There was no significant difference of the a - L - fucosidase level among patients with other blood diseases before the treatment ( P > 0. 05 ) . After the treatment, there was no significant difference of a - L - fucosidase level among the ones with different blood diseases ( P > 0. 05 ) . After the treatment, the level in eases of different blood diseases groups significantly decreased ( P < 0. 05 ). Conclusion a - L -fucosidase level can be used as the reference to the diagnosis and treatment effects on patients with hematopathy.
展开▼
